BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22570655)

  • 1. Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis.
    Li H; Hodgson E; Watson L; Shukla A; Nelson JJ
    J Cancer Epidemiol; 2012; 2012():291704. PubMed ID: 22570655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Related to Prostate-Specific Antigen-Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years.
    Rat C; Schmeltz H; Rocher S; Nanin F; Gaultier A; Nguyen JM
    JMIR Public Health Surveill; 2018 Oct; 4(4):e10352. PubMed ID: 30355559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year downstream outcomes following prostate-specific antigen screening in older men.
    Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
    JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
    Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
    Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
    Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
    JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
    Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
    BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathology grade influences competing mortality risks in elderly men with prostate cancer.
    Alam MU; Kumar J; Norez D; Tanneru K; Jazayeri SB; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Gautam S; Balaji KC
    Urol Oncol; 2021 Aug; 39(8):493.e1-493.e7. PubMed ID: 33353870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
    Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C
    BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
    Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
    Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Prostate-Specific Antigen Screening on Prostate Cancer Incidence and Mortality in China: 13-Year Prospective Population-Based Cohort Study.
    Ruan X; Zhang N; Wang D; Huang J; Huang J; Huang D; Chun TTS; Ho BSH; Ng AT; Tsu JH; Zhan Y; Na R
    JMIR Public Health Surveill; 2024 Jan; 10():e47161. PubMed ID: 38236627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunistic prostate cancer screening: A population-based analysis.
    Matti B; Zargar-Shoshtari K
    Urol Oncol; 2020 May; 38(5):393-400. PubMed ID: 31952998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate carcinoma among men with human immunodeficiency virus infection.
    Crum NF; Spencer CR; Amling CL
    Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis.
    Pathirana T; Sequeira R; Del Mar C; Dickinson JA; Armstrong BK; Bell KJL; Glasziou P
    Cancer Epidemiol; 2022 Apr; 77():102093. PubMed ID: 35026706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.
    Bryant AK; Lee KM; Alba PR; Murphy JD; Martinez ME; Natarajan L; Green MD; Dess RT; Anglin-Foote TR; Robison B; DuVall SL; Lynch JA; Rose BS
    JAMA Oncol; 2022 Dec; 8(12):1747-1755. PubMed ID: 36279204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications.
    Nordström T; Clements M; Karlsson R; Adolfsson J; Grönberg H
    Eur J Cancer; 2015 Apr; 51(6):725-33. PubMed ID: 25727881
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.